Patents by Inventor Maria Rita Fontana
Maria Rita Fontana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10988511Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.Type: GrantFiled: July 7, 2010Date of Patent: April 27, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
-
Publication number: 20180298064Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 26, 2018Publication date: October 18, 2018Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
-
Patent number: 10058600Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: GrantFiled: October 27, 2014Date of Patent: August 28, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
-
Patent number: 10035826Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: May 9, 2016Date of Patent: July 31, 2018Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20160244489Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 9334313Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: June 2, 2014Date of Patent: May 10, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Patent number: 9101560Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: GrantFiled: May 29, 2013Date of Patent: August 11, 2015Assignee: GlaxoSmithKline Biologicals SAInventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20150110830Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Laura SERINO, Maria Rita FONTANA, Danilo GOMES MORIEL
-
Publication number: 20140356389Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Patent number: 8871214Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.Type: GrantFiled: July 16, 2010Date of Patent: October 28, 2014Assignee: Novartis AGInventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
-
Patent number: 8758764Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: GrantFiled: February 17, 2006Date of Patent: June 24, 2014Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter InstituteInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Patent number: 8642050Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.Type: GrantFiled: February 16, 2009Date of Patent: February 4, 2014Assignee: Novartis AGInventors: Maria Rita Fontana, Mariagrazia Pizza, Vega Masignani, Elisabetta Monaci
-
Publication number: 20130323274Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: NOVARTIS AGInventors: Laura SERINO, Mariagrazia PIZZA, Danilo GOMES MORIEL, Maria Rita FONTANA
-
Patent number: 8470341Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: GrantFiled: February 23, 2009Date of Patent: June 25, 2013Assignee: Novartis AGInventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20130004531Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRLInventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
-
Publication number: 20120207777Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (or B526) protein.Type: ApplicationFiled: July 16, 2010Publication date: August 16, 2012Applicant: NOVARTIS AGInventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20120207776Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.Type: ApplicationFiled: July 7, 2010Publication date: August 16, 2012Applicant: NOVARTIS AGInventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20120058146Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: ApplicationFiled: November 9, 2011Publication date: March 8, 2012Applicant: Novartis Vaccines and Diagnostics SRLInventors: Danilo Gomes Moriel, Francesco Berlanda Scorza, Mariagrazia PIZZA, Laura Serino, Maria Rita Fontana
-
Patent number: 8062644Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: GrantFiled: February 17, 2006Date of Patent: November 22, 2011Assignee: Novartis Vaccines & Diagnostics SRL.Inventors: Mariagrazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20110091492Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.Type: ApplicationFiled: February 23, 2009Publication date: April 21, 2011Applicant: NOVARTIS AGInventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana